This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Randomized Controlled Trial  • Dermatology, Other  • Alert me on articles by topic

Arch Dermatol. 2000;136:775-776.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Erythromycin in pityriasis rosea: a double-blind, placebo-controlled clinical trial
Sharma PK, Yadav TP, Gautam RK, Taneja N, Satyanarayana L
J Am Acad Dermatol. 2000;42:241-244

Sharma et al conducted a trial whose results were remarkable and unexpected. The trial was a double-masked, placebo-controlled trial of erythromycin in the treatment of pityriasis rosea. The patients were children and adults with clinically diagnosed pityriasis rosea. Adult patients were treated with 250 mg of erythromycin 4 times daily and children were treated with 20 to 40 mg/kg daily in 4 divided doses. Controls were given placebo pills or syrup that was identical in appearance. The outcomes of complete, partial, and no clearing of the rash within 2 weeks were assessed by investigators who were unaware of the treatment allocation.

The results were that 33 (73%) of 45 patients who received erythromycin were completely clear at 2 weeks vs 0 of 45 patients receiving placebo. . . . [Full Text of this Article]

Editor's Comment

RELATED ARTICLE

Odds Ratios and Relative Risks
Michael Bigby
Arch Dermatol. 2000;136(6):770-772.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Azithromycin Does Not Cure Pityriasis Rosea
Amer and Fischer
Pediatrics 2006;117:1702-1705.
ABSTRACT | FULL TEXT